Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 4Active not recruiting 3Terminated 2Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Breast 1

Conditions

Breast Neoplasms 17Neoplasm Metastasis 6Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Colorectal Neoplasms 2Solid Cancer 1Salivary Gland Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neoplasm, Residual 1HER2-positive Breast Cancer 1HER2-mutant Non-Small Cell Lung Cancer 1HER2-Positive Primary Breast Cancer 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Breast Diseases 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Carboplatin 85pembrolizumab 78Pemetrexed 68Cisplatin 56Paclitaxel 45osimertinib 41Nivolumab 40durvalumab 37Docetaxel 33atezolizumab 20Gemcitabine 18Radiotherapy 17Radiosurgery 16amivantamab 15Ipilimumab 15130-nm albumin-bound paclitaxel 14Taxes 13Specimen Handling 12Magnetic Resonance Spectroscopy 12Crizotinib 11lazertinib 9Radiation 9Immunoglobulin G 9Drug Therapy 9Disulfides 9Bevacizumab 9tislelizumab 8cemiplimab 8alectinib 8Erlotinib Hydrochloride 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Non-Small-Cell Lung × trastuzumab deruxtecan × Clear all
NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

AstraZeneca

Phase 3 Active not recruiting
454 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04042701 2025-11-18

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 1 Active not recruiting
115 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03334617 2025-10-27

HUDSON

AstraZeneca

Phase 2 Active not recruiting
528 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡